XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Leases | 3 Months Ended
--- | ---
Mar. 31, 2024
Leases [Abstract] |
Leases | Leases The Company’s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred. The following table summarizes the Company’s future minimum operating lease commitments, including expected lease incentives to be received, as of March 31, 2024 (in thousands):
Year Ending December 31: |
2024 (remaining nine months) | $ | 8,688 |
2025 | 11,859 |
2026 | 12,209 |
2027 | 12,569 |
2028 | 12,940 |
Thereafter | 22,585 |
Total undiscounted lease payments | 80,850 |
Less: imputed interest | (19,024) |
Total operating lease liabilities | $ | 61,826 |
Reported as of March 31, 2024: |
Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities) | $ | 6,667 |
Operating lease liabilities, non-current | 55,159 |
Total | $ | 61,826 |
The operating lease costs for all operating leases were $2.3 million and $2.1 million for the three months ended March 31, 2024 and 2023, respectively. The operating lease costs and total commitments for short-term leases were de minimis for the three months ended March 31, 2024 and 2023. Variable lease costs for operating leases were $2.3 million and $1.4 million for the three months ended March 31, 2024 and 2023, respectively. The weighted-average remaining lease terms for operating leases were 6.6 and 6.8 years as of March 31, 2024 and December 31, 2023, respectively. The weighted‑average discount rate for operating leases was 8.5% as of both March 31, 2024 and December 31, 2023. In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately 11,000 square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $0.2 million for both the three months ended March 31, 2024 and 2023. In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (“Sonoma”), a related party, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. See Note 12, Related-Party Transactions. As a part of the sublease, in September 2021, the Company received a $4.6 million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $0.5 million for both the three months ended March 31, 2024 and 2023. The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.
Leases | Leases The Company’s lease portfolio is comprised of operating leases for laboratory, office and manufacturing facilities located in South San Francisco, California, and Seattle and Bothell, Washington with contractual periods expiring between December 2028 and March 2031. In addition to minimum rent, the leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred. The following table summarizes the Company’s future minimum operating lease commitments, including expected lease incentives to be received, as of March 31, 2024 (in thousands):
Year Ending December 31: |
2024 (remaining nine months) | $ | 8,688 |
2025 | 11,859 |
2026 | 12,209 |
2027 | 12,569 |
2028 | 12,940 |
Thereafter | 22,585 |
Total undiscounted lease payments | 80,850 |
Less: imputed interest | (19,024) |
Total operating lease liabilities | $ | 61,826 |
Reported as of March 31, 2024: |
Short-term portion of lease liabilities (included in accrued liabilities and other current liabilities) | $ | 6,667 |
Operating lease liabilities, non-current | 55,159 |
Total | $ | 61,826 |
The operating lease costs for all operating leases were $2.3 million and $2.1 million for the three months ended March 31, 2024 and 2023, respectively. The operating lease costs and total commitments for short-term leases were de minimis for the three months ended March 31, 2024 and 2023. Variable lease costs for operating leases were $2.3 million and $1.4 million for the three months ended March 31, 2024 and 2023, respectively. The weighted-average remaining lease terms for operating leases were 6.6 and 6.8 years as of March 31, 2024 and December 31, 2023, respectively. The weighted‑average discount rate for operating leases was 8.5% as of both March 31, 2024 and December 31, 2023. In May 2021, the Company entered into a sublease, whereby the Company agreed to sublease approximately 11,000 square feet of its space in South San Francisco, California currently leased by the Company. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized sublease income for this sublease of $0.2 million for both the three months ended March 31, 2024 and 2023. In September 2021, the Company entered into a sublease with Sonoma Biotherapeutics, Inc. (“Sonoma”), a related party, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. See Note 12, Related-Party Transactions. As a part of the sublease, in September 2021, the Company received a $4.6 million tenant improvement contribution payment, which is recognized over the term of the sublease. The sublease is classified as an operating lease and will expire in March 2031. The Company recognized Sonoma sublease income of $0.5 million for both the three months ended March 31, 2024 and 2023. The Company's sublease income is recognized within other operating income, net in the Condensed Consolidated Statements of Operations and Comprehensive Loss.

X
- References No definition available. + Details
Name: | us-gaap_LeasesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//842-20/tableOfContent + Details
Name: | us-gaap_LesseeOperatingLeasesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for lessor's operating leases. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//842-30/tableOfContent + Details
Name: | us-gaap_OperatingLeasesOfLessorDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration